Form 8-K - Current report

Merck Announces Second-Quarter 2024 Financial Results

Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11...

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Opinion granted based on positive overall survival and progression-free survival results from the Phase 3 KEYNOTE-A39 trial Positive opinion...

Merck Announces Fourth-Quarter 2024 Dividend

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly...

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today...

Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024

Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK...

Merck Completes Acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema...

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business

Acquisition delivers industry-leading portfolio, scientific and research capabilities, for enhanced customer benefits Merck Animal Health, known...

Elanco Completes Sale of Aqua Business

Elanco Completes Sale of Aqua Business PR Newswire GREENFIELD, Ind., July 9, 2024 Transaction concentrates...

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation (“Orion”) today announced that notice has been...

Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2024 sales and earnings conference call...

Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)

If approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor therapy for PAH in Europe, offering a new...

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

CAPVAXIVE (V116) recommended for all adults age 65 and older and for adults 19 to 64 with certain risk conditions, and for those over 65...

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

The letter did not identify any issues with the efficacy or safety data submitted in the application The U.S. Food and Drug Administration (FDA...

USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease Merck Animal Health, known as...